Journal article

PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Murphy, F., Church, D., Medley, L., Davies, J., Breen, D., Clelland, C., Mackintosh, D., Mugalaasi, H., Butler, R., & Talbot, D. (2011). PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR. JOURNAL OF THORACIC ONCOLOGY, 6(6), S1250–S1250.

MLA Style

Murphy, F, et al. “PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR.” JOURNAL OF THORACIC ONCOLOGY, vol. 6, no. 6, 2011, pp. S1250–S1250.

Chicago Style

Murphy, F, D Church, L Medley, et al. 2011. “PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR.” JOURNAL OF THORACIC ONCOLOGY 6 (6): S1250–S1250.
Print

Authors

+ Murphy, F More by this author

Role:: Author

+ Church, D More by this author

Role:: Author

+ Medley, L More by this author

Role:: Author

+ Davies, J More by this author

Role:: Author

+ Breen, D More by this author

Role:: Author

More authors...

Journal:: JOURNAL OF THORACIC ONCOLOGY More from this journal
Volume:: 6
Issue:: 6
Pages:: S1250-S1250
Publication date:: 2011-06-01
ISSN:: 1556-0864

Keywords:: NSCLC

EGFR

erlotinib

first-line
Pubs id:: pubs:164208
UUID:: uuid:00e01c4e-f732-4b77-b54d-c83c8064b975
Local pid:: pubs:164208
Source identifiers:: 164208
Deposit date:: 2013-11-16
ARK identifier:: ark:/29072/ora_00e01c4ef7324b77b54dc83c8064b975

Terms of use

Copyright date:: 2011

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP